(RTTNews) - Tuesday, BeyondSpring (BYSI) said the FDA granted Fast Track designation to Plinabulin plus docetaxel for advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) following progression on immune checkpoint inhibitor therapy and chemotherapy.
Plinabulin is an investigational small-molecule cancer therapy being evaluated for its anticancer and immune-modulating effects.
The Phase 3 DUBLIN-4 study plans to enroll 442 patients and compare Plinabulin plus docetaxel with docetaxel alone, with overall survival as the primary endpoint.
BeyondSpring also entered a strategic transaction under which an investor will fund the China portion of DUBLIN-4, expected to account for about half of total enrollment.
BeyondSpring's closed Monday's trading at $1.12, up 44.11%. In the premarket trading, the stock is at $1.03, down 8.04%.
© 2026 J2T Services Ltd
J2T Services Ltd is authorised and regulated by the Cyprus Securities and Exchange Commission in accordance with license No.281/15 issued on 25/09/2015. The "Just2Trade" trademark is owned by J2T SERVICES LTD.
Registration Number: HE 341520
Address: J2T Services Ltd
Magnum Business Center, Office 4B, Spyrou Kyprianou Avenue 78
Limassol 3076, Cyprus
Disclaimer: All promotions, materials and information of this website may have applied conditions. Please contact the Company for further details
Trading on financial markets carries risks. The value of the investments can both increase and decrease and the investors may lose all their investment capital. In case of a leveraged product, the loss may be more than the initial capital invested. Detailed information on risks associated with trading on financial markets can be found in General Terms and Conditions for the Provision of Investment Services.
E-mail: 24_support@j2t.com
